Company: LBRX
Filing Date: 2025-09-08
Form Type: S-1/A
Source: 0001193125-25-197877
Chunk: 17

Company: LB PHARMACEUTICALS INC
Filing Date: 2025-09-08
Form: S-1/A
Chunk 17
---
 set forth on the cover page of the prospectus, upon the execution of the underwriting agreement related to this offering, stock options to purchase approximately 406,998 shares of our common stock will be automatically repriced to an exercise price per share equal to the initial price per share to the public in this offering. Unless otherwise indicated, all information contained in this prospectus assumes or gives effect to:

9

| • |     | the automatic conversion of an aggregate of all 4,251,960 shares of our Series Seed convertible preferred stock,                                                                                          
 Series A convertible preferred stock and Series B convertible preferred stock outstanding prior to the Stock Split into an aggregate of 152,390 shares of common stock upon the closing of this offering; |

| • |     | the automatic conversion of all 73,820,346 shares of our Series C convertible preferred stock outstanding prior                                                                                                                                         
 to the Stock Split into 3,029,425 shares of our common stock, including 382,467 shares of common stock issuable in respect of anti-dilution adjustments, upon the closing of this offering, based upon an assumed initial public offering price of      
 $15.00 per share, which is the midpoint of the estimated offering price range set forth on the cover page of this prospectus. A $1.00 decrease in the initial public offering price would increase the number of shares of our common stock             
 issuable in respect of our Series C convertible preferred stock by 19,731 shares, and a $1.00 increase in the initial public offering price would decrease the number of shares of our common stock issuable in respect of our Series C convertible     
 preferred stock by 19,254 shares; provided, however, that in no event would the shares of our Series C convertible preferred stock outstanding prior to the Stock Split convert into more than 3,049,156 shares of our common stock upon the closing of 
 this offering. A 1.0 million share increase in the size of this offering would increase the number of shares of our common stock issuable in respect of our Series C convertible preferred stock by 4,261 shares, and a 1.0 million share               
 decrease in the size of this offering would decrease the number of shares of our common stock issuable in respect of our Series C convertible preferred stock by 4,795 shares;                                                                          |

| • |     | the filing of our amended and restated certificate of incorporation and the adoption of our amended and restated 
 bylaws immediately prior to the closing of this